Best PET-CT with Gallium 68 (DOTATATE) Doctors Abroad

Dr. Elad Jacoby is a pioneer of pediatric CAR T–cell therapy in Israel. He heads the Pediatric Cell Therapy Center at Sheba Medical Center. Dr. Jacoby specializes in treating relapsed and high-risk pediatric leukemias and lymphomas. He completed fellowships at Johns Hopkins and the U.S. National Cancer Institute.

• Medical Director of the Advanced Biotherapy Center at Sheba Medical Center.
• Authored over 240 scientific publications in pediatric hemato-oncology.
• Board-certified in both Pediatrics and Pediatric Hematology and Oncology.
• Leads the integration of CAR T–cell therapy with bone marrow transplantation.

Uzm. Dr. Erkan Göcen is a Radiation Oncology Specialist at Çerkezköy Private Optimed Hospital (Optimed Health Group). He graduated from İstanbul University, İstanbul Faculty of Medicine (Çapa) in 2003.

Career: He trained and practiced in Radiation Oncology from 2010 to 2012. He worked in public and private health institutions from 2012 to 2016. He served in the private medical sector as a Radiation Oncology Specialist from 2016 to 2023. He has been at Optimed Hospital since 2024.

Clinical interests: cancers of the brain, head and neck, esophagus, stomach, colorectal, pancreas, prostate, bladder, lung, soft tissues (sarcomas), skin, uterus and cervix, and breast. Affiliations: Turkish Society for Radiation Oncology (TROD) and Tekirdağ Medical Chamber. Languages: English and Turkish.

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

Assoc. Prof. Priv.-Doz. Dr. Alexander W. Hauswirth is a specialist in internal medicine and haemato‑oncology at JUVENIS. Since 2010, he has served as the lead senior physician for Haematology/Haemostaseology and Oncology at the Clinic for Internal Medicine I, Medical University of Vienna/AKH Vienna, Austria’s largest hospital.

He earned his medical degree from the University of Vienna in 1999. He received the venia docendi in 2010 and was appointed Associate Professor in 2012. He completed an additional haemato‑oncology qualification in 2014. As a Schrödinger Fellow in Salamanca in 2009–2010, he researched CLL stem and precursor cells. He has published regularly since 2000.

Accreditations include Austrian Medical Chamber diplomas in emergency medicine (since 2009) and sports medicine (2018). Awards include the Schrödinger Fellowship (2009), the ÖGHO award (2009), and the European Society of Chemotherapy poster award (2003). Clinical focus: anaemias, leukaemias, lymph node disorders, clotting and anticoagulation, and pre‑operative clearance. Languages: German and English.

Dr. med. univ. Negar Fakhrai is a radiology specialist at JUVENIS Medical Center in Vienna. She performs diagnostic ultrasound. She has more than 20 years of experience in university, trauma, and private hospitals. She treats patients in German, English, Farsi, and French.

Education: MD, 2001. Her dissertation quantified coronary artery calcification with electron-beam computed tomography. Training in internal medicine and oncology at the Medical University of Vienna with CECOG (2001–2004). Radiology training at the University Clinic (2005–2013). Radiology specialist exam in 2010.

Career: Lorenz Böhler Trauma Hospital (2013–2021). Private clinics since 2016. Rudolfinerhaus (2021–2022). Independent since 2023, including Wiener Privatklinik. Joined JUVENIS in 03/2024. Strong focus on musculoskeletal imaging.

Awards/research: Investigator Award, University Clinic for Radiodiagnostics, Medical University of Vienna (2010). Publications in the American Journal of Neuroradiology, European Journal of Radiology, and Journal of Neuro-Oncology. Ultrasound: abdomen; vascular (carotids, deep leg veins); breast; thyroid/neck; muscles/joints; soft tissue; testes.

Dr. Zulfu Sertkaya is an associate professor and andrologist at Andro Expertise in Istanbul. He holds the FEBU title from the European Association of Urology. Dr. Sertkaya focuses on male health, sexual function, and aesthetic urological procedures. He treats patients at his clinic and performs surgeries at affiliated hospitals.

• Earned Fellow of the European Board of Urology (FEBU) status.
• Specialize in andrology, male sexual health, and aesthetic urology.
• Performs penile implant surgery and varicocelectomy for infertility.
• Works at a clinic accredited by the Turkish Medical Association.

Dr. Burak Ergun Tatar is a plastic surgeon at Medipol Acibadem District Hospital in Istanbul. He specializes in transformative cosmetic and reconstructive surgeries, including facelifts, rhinoplasty, and breast augmentation. Dr. Tatar completed a microsurgery fellowship at Università Campus Bio-Medico in Rome. He graduated with distinction from the Istanbul University School of Medicine.

• Holds specialized certifications in microsurgery, animal research, and medical statistics.
• Performs complex body contouring like tummy tucks, liposuction, and mommy makeovers.
• Treats functional and aesthetic conditions, including deviated septums and gynecomastia.
• Works at a JCI-accredited facility using the da Vinci robotic system.

Dr. Gokhan Yilmaz is a general surgeon at Medipol University Pendik Hospital in Istanbul. He specializes in colorectal, gastrointestinal, and bariatric surgery. Dr. Yilmaz previously served as an Assistant Professor at Istanbul Medipol University. He trained at Okmeydanı Training and Research Hospital, a top Turkish medical institution.

• Performs complex procedures like gastric sleeve, gastric bypass, and gastric balloon.
• Treats conditions including inguinal hernias, pancreatic cysts, and fibrocystic breast disease.
• Conducted surgical research and trained new surgeons as a university faculty member.
• Works at a facility that earned 95.4 out of 96.4 points for healthcare quality.

The doctor is a highly experienced medical professional with over two decades of clinical practice. Having completed medical training at Istanbul University's Faculty of Medicine in 1996, the doctor went on to specialize at the SSK Okmeydanı Training and Research Hospital in 2000.

Throughout a distinguished career, the doctor has held positions at various reputable institutions, including the Kayseri Military Hospital, SSK Yalova Regional Hospital, and Private Avicenna Umut Hospital. Most recently, the doctor has contributed expertise to Private Adatıp Kurtköy Hospital and Istanbul Medipol University Pendik Hospital, demonstrating a consistent commitment to patient care and clinical excellence across multiple healthcare settings.

Dr. Atakan Topcu is a medical oncologist at Medipol Acibadem District Hospital in Istanbul. He specializes in treating solid tumors including lung, breast, and colorectal cancers. Dr. Topcu is an Associate Professor with over 50 peer-reviewed scientific publications. He sits on the Editorial Board of the medical journal BMC Cancer.

• Expertise in immunotherapy, targeted therapies, and geriatric oncology care.
• Treats cancer-related malnutrition, cachexia, and sarcopenia.
• Maintains active membership in the European Society for Medical Oncology (ESMO).
• Works at a JCI-accredited hospital specializing in advanced oncology treatments.

Dr. Nail Paksoy is an associate professor of medical oncology at Medipol Bahçelievler Hospital. He is board-certified by the European Society for Medical Oncology (ESMO). Dr. Paksoy specializes in lung, breast, and gastrointestinal cancers. He uses modern immunotherapy and targeted therapy protocols. His clinic is JCI-accredited for high safety standards.

• Served as a subinvestigator in over 8 international clinical trials for Roche and Pfizer.
• Authored over 40 research articles in journals indexed by SCI and SSCI.
• Completed dual fellowships in allergy-immunology and medical oncology.
• Treats complex sarcomas and renal cell carcinomas with systemic therapies.

Dr. Gul Alco is a radiation oncologist and Professor at Medipol Acibadem District Hospital in Istanbul. She excels in treating complex cases, including stage 4 lung and liver cancers. Dr. Alco utilizes the CyberKnife and Da Vinci robotic systems for precise tumor targeting. She works at a JCI-accredited facility known for its high safety standards.

• Specializes in brachytherapy and high-intensity focused ultrasound ablation (HIFU).
• Performs radiofrequency ablation and proton-beam therapy for various malignancies.
• Treats pancreatic, breast, ovarian, and brain cancers using targeted radiation.
• Expert in nuclear medicine diagnostics, including PET-CT with Gallium 68.

Dr. Elnur Sahibov is a radiation oncology specialist at Emsey Hospital. He completed his medical training at the prestigious Marmara University.

• Specialized in radiation oncology at Marmara University Faculty of Medicine
• Completed medical training in English at Marmara University
• Focuses on precision imaging for PET-CT with Gallium 68 (DOTATATE)
• Works at Emsey Hospital, a major multidisciplinary medical center
• Expert in identifying and localizing neuroendocrine tumors for treatment

Dr. Caglayan Altinbas is a physician at Medipol University Pendik Hospital in Istanbul. He specializes in rehabilitation for complex spinal cord injuries and pediatric cerebral palsy. Dr. Altinbas earned his medical degree from Marmara University and completed residency at Bezmialem Vakif University. He holds a certificate in Physical Medicine and Rehabilitation.

• Expertise includes orthopedic recovery and pediatric physical therapy programs.
• Treats patients at a clinic scoring 95.4 out of 96.4 for quality standards.
• Performs specialized rehabilitation for children with motor disabilities.
• Practices at a university-affiliated center serving 350,000 patients annually.

Prof. Dr. Abdullah Sakin is a professor of medical oncology. He treats solid tumors, including lung, breast, gastrointestinal, genitourinary, gynecologic, head and neck cancers, and melanoma.

He delivers personalized, evidence-based care. His treatments include chemotherapy, targeted therapy, immunotherapy, hormone therapy, and precision oncology. He has authored more than 200 scientific publications and takes part in international clinical research. This work advances patient-centered cancer care.

Dr. Antonio Cubillo Gracián leads the Medical Oncology Service at HM Sanchinarro. He pioneered liquid biopsy programs for moleliar tumor analysis in Spain.

• Specializes in digestive and lung cancers identified through PET-CT with Gallium 68 diagnostics
• Director of Postgraduate Research at HM CIOCC specializing in oncologic research
• Director of the Clinical and Applied Research in Oncology Master’s program
• Co-investigator for the Start Madrid program focusing on new clinical trials
• Associate Professor of Oncology at USP CEU University in Madrid

Dr. Sridhar P.S. is a specialist in radiotherapy and neuro-oncology at HCG Manavata Cancer Centre. He performs PET-CT with Gallium 68 for precise tumor imaging.

• Holds a Doctor of Medicine in radiotherapy from Banaras Hindu University
• Diplomate of the National Board in radiotherapy oncology
• Member of the Society for Neuro-Oncology – focusing on brain tumor research
• Affiliated with the Indian Association of Hyperthermia Oncology
• Expert in radiation oncology for cancer detection and staging

Dr. Chaitainya Borde has handled over 30,000 PET scans. He leads nuclear medicine services at HCG Manavata Cancer Centre.

• Specializes in PET-CT with Gallium 68 for precise tumor imaging
• Expert in nuclear cardiology and specialized radioiodine therapies
• Performed Lu-177 RN therapies for advanced cancer cases
• Published research papers in various medical journals
• Managed treatments for 1,000 thyroid cancer patients

Dr. Shruti Kate is a medical oncology expert at HCG Manavata Cancer Centre. Her work involves advanced PET-CT with Gallium 68 for staging solid tumors.

• Previously served as a consultant at Tata Memorial Hospital in Mumbai
• Earned a DM in Medical Oncology from Tata Memorial Hospital
• Received a travel award for lung cancer research at WCLC 2018
• Member of the American Society of Clinical Oncology (ASCO)
• Belongs to the European Society for Medical Oncology (ESMO)